Cited by CrossRef (5)

  1. Kaige Zheng, Muyan Chen, Xingjianyuan Xu, Peiyi Li, Chengyu Yin, Jie Wang, Boyi Liu. Chemokine CXCL13–CXCR5 signaling in neuroinflammation and pathogenesis of chronic pain and neurological diseases. Cell Mol Biol Lett 2024;29
    https://doi.org/10.1186/s11658-024-00653-y
  2. Yu-Mi Kim, Jo-Young Son, Dong-Kuk Ahn. Botulinum toxin type A is a potential therapeutic drug for chronic orofacial pain. Journal of Oral Biosciences 2024;66:496
    https://doi.org/10.1016/j.job.2024.06.004
  3. Ana Bagues, Jiaxin Hu, Ishraq Alshanqiti, Man-Kyo Chung. Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain. Pharmacology & Therapeutics 2024;259:108668
    https://doi.org/10.1016/j.pharmthera.2024.108668
  4. Katarzyna Pawlik, Joanna Mika. Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain. Molecules 2023;28:5766
    https://doi.org/10.3390/molecules28155766
  5. Dalia Nemanić, Matej Mustapić, Ivica Matak, Lidija Bach-Rojecky. Botulinum toxin type a antinociceptive activity in trigeminal regions involves central transcytosis. European Journal of Pharmacology 2024;963:176279
    https://doi.org/10.1016/j.ejphar.2023.176279